The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer

Inclusion Criteria

• •1. Aged \>=18 years old.
• •2. Patients with metastatic castration-resistant prostate cancer who have failed standard treatments.
• •3. According to RECIST 1.1, there is at least one measurable lesion.
• •4. ECOG performance status 0-1.
• •5. Laboratory examination should meet: ① Blood routine: hemoglobin (HGB) ≥90g/L, neutrophil count (ANC) ≥1.5×10\^9/L, platelet count ( PLT) ≥100×10\^9/L; ②Blood biochemistry: total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0×ULN, serum creatinine ( Cr)≤1.5×ULN or calculate the creatinine clearance ≥50 mL/min according to the Cockcroft-Gault formula method.